DUBLIN, Ohio, Aug. 21, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today its plans to open a new distribution center in Walton Hills, Ohio, supporting its U.S. Medical Products and Distribution business. The facility will integrate new technology solutions, deliver operational efficiencies, and provide expanded capacity in the Cleveland, Ohio area. With construction underway, the distribution center is anticipated to be fully operational in the spring of 2025 and, at nearly 249,000 square feet, is more than 30% larger than the Cardinal Health location in nearby Solon, Ohio, it will replace. The larger building and its operations will accommodate a full transition of employees.
"We're proud to expand our capabilities in Northeast Ohio, which is a major healthcare hub and a critical market that our medical products and distribution business has serviced for more than 25 years," said Sherrick Orie, vice president, Central Region Operations. "This distribution center will feature technology and automation to improve quality of service for our customers and day-to-day work experiences for our employees, as well as the additional storage capacity essential to meeting our customers' growing needs."
Next generation technology integrated into the building will improve workflows and help move medical products through the building more efficiently, enhancing the order-to-delivery experience for customers. Working alongside employees, automation will drive productivity and performance, while reducing risks of ergonomic injuries.
"Cardinal Health is investing in a state-of-the art building in a prime location," said Walton Hills Mayor Don Kolograf. "We are excited to welcome the company to the new Forward Innovation Center (East) industrial park, Northeast Ohio's revitalized development space for modern manufacturing and distribution operations. We look forward to working with their team and making Walton Hills a vital area for Cardinal Health's growing operations in Ohio."
Cardinal Health's investment in the new facility is part of a larger strategy to best serve healthcare customers and the patients they care for. Expanding its U.S. Medical Products and Distribution footprint and implementing new technology solutions illustrates the company's continued focus on infrastructure, warehouse operations and supply chain resiliency. In 2023, Cardinal Health opened two new distribution centers in Central Ohio to support is U.S. Medical Products and Distribution and at-Home Solutions businesses, and a new medical products replenishment center in Montgomery, N.Y., which strengthens on-hand inventory levels and the ability to rapidly restock its distribution network. In late 2024, Cardinal Health will celebrate the recent opening of a new distribution center in the Boston, Mass., area, providing expanded warehouse capacity and specialized handling capabilities for products requiring refrigeration.
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, operations in more than 30 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.
Contacts
Media: Brittany Julian, This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors: Matt Sims, This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$116.13 |
Daily Change: | 8.24 7.64 |
Daily Volume: | 3,343,089 |
Market Cap: | US$28.100B |
November 01, 2024 October 29, 2024 September 20, 2024 September 17, 2024 August 14, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB